#United States #Las Vegas #Clinical Trials #VIVA Foundation #Vascular Medicine

Groundbreaking Clinical Trial Results Announced at VIVA 2026

The VIVA Foundation, a prominent non-profit organization committed to enhancing vascular medicine and intervention through research and education, recently showcased remarkable findings from late-breaking clinical trials at the VIVA 2026 conference held in Las Vegas. This annual event is known for its dedication to sharing cutting-edge clinical data and innovations in vascular health.

About VIVA

For over two decades, VIVA (Vascular InterVentional Advances) has established itself as a leading institution in the field of peripheral vascular disease. It regularly unites healthcare professionals, researchers, and industry leaders to disseminate the latest scientific advancements and clinical best practices.

Highlights of Late-Breaking Trials

In a particularly notable session, several clinical trials were presented, each focusing on cutting-edge technologies and methodologies aimed at improving outcomes for patients with peripheral artery disease (PAD).

1. SELUTION4SFA Study Results:

One of the most anticipated presentations came from the SELUTION4SFA trial, led by Dr. Jay Mathews. The study was a randomized controlled trial comparing the SELUTION SLR™ (Sustained Limus Release) Drug-Eluting Balloon (DEB) with traditional balloon angioplasty for treating patients suffering from symptomatic PAD in the superficial femoral artery and proximal popliteal artery. Conducted across 34 sites, the trial enrolled 300 subjects, providing crucial insights into the efficacy and safety of this innovative treatment.

Key findings indicated that the SELUTION SLR™ DEB achieved a primary patency rate of 90.3% at 12 months compared to 79.4% in the control group treated with balloon angioplasty, demonstrating a significant improvement in outcomes.

2. SirPAD Trial Insights:

Dr. Stefano Barco presented secondary analyses from the SirPAD trial, which evaluated sirolimus-coated balloons versus uncoated balloons in patients with femoropopliteal lesions. This significant comparative analysis found that the sirolimus-coated balloons markedly reduced the rate of target-lesion revascularization and major limb events over one year when compared to traditional balloons.

3. SUCCESS PTA Study Results:

The SUCCESS PTA Study, presented by Dr. Thomas Zeller, offered insights into the long-term performance of the SELUTION SLR™ in a real-world cohort. This study demonstrated a freedom from clinically driven target lesion revascularization of 86.1% at the 24-month mark, cementing the DEB's relevance in everyday clinical practice.

Emerging Therapeutic Options

In addition to the above, emerging therapies were discussed, including the use of montelukast for reducing major adverse limb events post-endovascular treatment. Dr. Mikołaj Maga reported significant findings that indicated montelukast may lessen complications and improve patient outcomes, showcasing the potential for innovative pharmacological strategies in vascular medicine.

The Role of Technology

The conference also featured discussions on the latest technological advancements in the field, emphasizing the importance of integrating new devices and treatment modalities to enhance patient care. Among the innovations addressed were drug-eluting scaffolds and advanced thrombectomy systems, both of which promise to refine treatment approaches for complex vascular conditions.

A Platform for Collaboration

The VIVA 2026 conference underscores the essential role of collaboration among specialists across various vascular disciplines. By providing a platform for education and discourse, the event facilitates the exchange of transformative ideas and practices that could shape the future of vascular medicine.

Conclusion

As vascular medicine continues to evolve, events like VIVA 2026 not only highlight significant clinical milestones but also set the stage for future explorations that aim to improve patient outcomes worldwide. The collective expertise and research presented at this year's conference resonate with the foundation’s mission of advancing healthcare through innovation and education.

To discover more about the VIVA Foundation and its ongoing efforts to enhance vascular healthcare, you can visit their official website at VIVA Foundation.